Transcriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophrenia

Schizophrenia Research

Volumn 167, Issue 1-3, 2015, Pages 28-34

  Mitchell, Amanda C ^a   Jiang, Yan ^a   Peter, Cyril ^a   Akbarian, Schahram ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Epigenetics; GABA; GAD1; Prefrontal cortex; Transcription factors

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; TRANSCRIPTION FACTOR;

CHRONOLOGY; CONFORMATIONAL TRANSITION; DNA METHYLATION; EPIGENETICS; GABAERGIC SYSTEM; GAD1 GENE; GENE EXPRESSION; GENE LOCATION; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; MARKER GENE; NONHUMAN; PREFRONTAL CORTEX; PRIMATE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SCHIZOPHRENIA; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; GENE EXPRESSION REGULATION; GLUTAMATE DECARBOXYLASE; HUMANS; PREFRONTAL CORTEX; SCHIZOPHRENIA; TRANSCRIPTION FACTORS;

EID: 84942193326     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.10.020     Document Type: Review

References (127)

1. Addington A.M., Gornick M., Duckworth J., Sporn A., Gogtay N., Bobb A., Greenstein D., Lenane M., Gochman P., Baker N., Balkissoon R., Vakkalanka R.K., Weinberger D.R., Rapoport J.L., Straub R.E. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol. Psychiatry 2005, 10(6):581-588.
2. Akbarian S., Huang H.S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res. Rev. 2006, 52(2):293-304.
3. Akbarian S., Bunney W.E., Potkin S.G., Wigal S.B., Hagman J.O., Sandman C.A., Jones E.G. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch. Gen. Psychiatry 1993, 50(3):169-177.
4. Akbarian S., Vinuela A., Kim J.J., Potkin S.G., Bunney W.E., Jones E.G. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch. Gen. Psychiatry 1993, 50(3):178-187.
5. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 1995, 52(4):258-266.
6. Anderson S.A., Volk D.W., Lewis D.A. Increased density of microtubule associated protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic subjects. Schizophr. Res. 1996, 19(2-3):111-119.
7. Andreassen O.A., Thompson W.K., Dale A.M. Boosting the power of schizophrenia genetics by leveraging new statistical tools. Schizophr. Bull. 2014, 40(1):13-17.
8. Asada H., Kawamura Y., Maruyama K., Kume H., Ding R.G., Kanbara N., Kuzume H., Sanbo M., Yagi T., Obata K. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(12):6496-6499.
9. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., Quinlan E.M., Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 2010, 13(1):76-83.
10. Benes F.M. A new paradigm for understanding gamma-aminobutyric acid cell pathology in schizophrenia?. Biol. Psychiatry 2012, 72(9):712-713.
11. Benes F.M., Sorensen I., Vincent S.L., Bird E.D., Sathi M. Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cereb. Cortex 1992, 2(6):503-512.
12. Benes F.M., Vincent S.L., Alsterberg G., Bird E.D., SanGiovanni J.P. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J. Neurosci. 1992, 12(3):924-929.
13. Benes F.M., Lim B., Matzilevich D., Walsh J.P., Subburaju S., Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(24):10164-10169.
14. Benson D.L., Huntsman M.M., Jones E.G. Activity-dependent changes in GAD and preprotachykinin mRNAs in visual cortex of adult monkeys. Cereb. Cortex 1994, 4(1):40-51.
15. Bernstein B.E., Birney E., Dunham I., Green E.D., Gunter C., Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489(7414):57-74.
16. Bharadwaj R., Jiang Y., Mao W., Jakovcevski M., Dincer A., Krueger W., Garbett K., Whittle C., Tushir J.S., Liu J., Sequeira A., Vawter M.P., Gardner P.D., Casaccia P., Rasmussen T., Bunney W.E., Mirnics K., Futai K., Akbarian S. Conserved chromosome 2q31 conformations are associated with transcriptional regulation of GAD1 GABA synthesis enzyme and altered in prefrontal cortex of subjects with schizophrenia. J. Neurosci. 2013, 33(29):11839-11851.
17. Bird E.D., Spokes E.G., Barnes J., MacKay A.V., Iversen L.L., Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet 1977, 2(8049):1157-1158.
18. Bu D.F., Tobin A.J. The exon-intron organization of the genes (GAD1 and GAD2) encoding two human glutamate decarboxylases (GAD67 and GAD65) suggests that they derive from a common ancestral GAD. Genomics 1994, 21(1):222-228.
19. Bullock W.M., Cardon K., Bustillo J., Roberts R.C., Perrone-Bizzozero N.I. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am. J. Psychiatry 2008, 165(12):1594-1603.
20. Catts V.S., Fung S.J., Long L.E., Joshi D., Vercammen A., Allen K.M., Fillman S.G., Rothmond D.A., Sinclair D., Tiwari Y., Tsai S.Y., Weickert T.W., Shannon Weickert C. Rethinking schizophrenia in the context of normal neurodevelopment. Front. Cell. Neurosci. 2013, 7:60.
21. Chattopadhyaya B., Di Cristo G., Wu C.Z., Knott G., Kuhlman S., Fu Y., Palmiter R.D., Huang Z.J. GAD67-mediated GABA synthesis and signaling regulate inhibitory synaptic innervation in the visual cortex. Neuron 2007, 54(6):889-903.
22. Chen Y., Dong E., Grayson D.R. Analysis of the GAD1 promoter: trans-acting factors and DNA methylation converge on the 5' untranslated region. Neuropharmacology 2011, 60(7-8):1075-1087.
23. Chen C.M., Stanford A.D., Mao X., Abi-Dargham A., Shungu D.C., Lisanby S.H., Schroeder C.E., Kegeles L.S. GABA level, gamma oscillation, and working memory performance in schizophrenia. Neuroimage Clin. 2014, 4:531-539.
24. Cheung I., Shulha H.P., Jiang Y., Matevossian A., Wang J., Weng Z., Akbarian S. Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(19):8824-8829.
25. Cho S.W., Kim S., Kim J.M., Kim J.S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013, 31(3):230-232.
26. Cieslik E.C., Muller V.I., Kellermann T.S., Grefkes C., Halfter S., Eickhoff S.B. Shifted neuronal balance during stimulus-response integration in schizophrenia: an fMRI study. Brain Struct. Funct. 2013, (Epub ahead of print). 10.1007/s00429-013-0652-1.
27. Condie B.G., Bain G., Gottlieb D.I., Capecchi M.R. Cleft palate in mice with a targeted mutation in the gamma-aminobutyric acid-producing enzyme glutamic acid decarboxylase 67. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(21):11451-11455.
28. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339(6121):819-823.
29. Cross A.J., Crow T.J., Owen F. Gamma-aminobutyric acid in the brain in schizophrenia. Lancet 1979, 1(8115):560-561.
30. Curley A.A., Arion D., Volk D.W., Asafu-Adjei J.K., Sampson A.R., Fish K.N., Lewis D.A. Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am. J. Psychiatry 2011, 168(9):921-929.
31. Dekker J., Marti-Renom M.A., Mirny L.A. Exploring the three-dimensional organization of genomes: interpreting chromatin interaction data. Nature Reviews Genetics 2013, 14(6):390-403.
32. Deng W., Blobel G.A. Do chromatin loops provide epigenetic gene expression states?. Curr. Opin. Genet. Dev. 2010, 20(5):548-554.
33. Diwadkar V.A., Pruitt P., Goradia D., Murphy E., Bakshi N., Keshavan M.S., Rajan U., Reid A., Zajac-Benitez C. Fronto-parietal hypo-activation during working memory independent of structural abnormalities: conjoint fMRI and sMRI analyses in adolescent offspring of schizophrenia patients. NeuroImage 2011, 58(1):234-241.
34. Dorph-Petersen K.A., Lewis D.A. Stereological approaches to identifying neuropathology in psychosis. Biol. Psychiatry 2011, 69(2):113-126.
35. Dracheva S., Elhakem S.L., McGurk S.R., Davis K.L., Haroutunian V. GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J. Neurosci. Res. 2004, 76(4):581-592.
36. Eack S.M., Wojtalik J.A., Newhill C.E., Keshavan M.S., Phillips M.L. Prefrontal cortical dysfunction during visual perspective-taking in schizophrenia. Schizophr. Res. 2013, 150(2-3):491-497.
37. Eastwood S.L., Harrison P.J. Interstitial white matter neuron density in the dorsolateral prefrontal cortex and parahippocampal gyrus in schizophrenia. Schizophr. Res. 2005, 79(2-3):181-188.
38. Fatemi S.H., Stary J.M., Earle J.A., Araghi-Niknam M., Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67kDa and Reelin proteins in cerebellum. Schizophr. Res. 2005, 72(2-3):109-122.
39. Fujiki R., Morita K., Sato M., Kamada Y., Kato Y., Inoue M., Shoji Y., Uchimura N. Reduced prefrontal cortex activation using the Trail Making Test in schizophrenia. Neuropsychiatr. Dis. Treat. 2013, 9:675-685.
40. Gaj T., Gersbach C.A., Barbas C.F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31(7):397-405.
41. Geffen Y., Keefe R., Rabinowitz J., Anand R., Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J. Clin. Psychiatry 2012, 73(9):e1168-e1174.
42. Gilabert-Juan J., Varea E., Guirado R., Blasco-Ibanez J.M., Crespo C., Nacher J. Alterations in the expression of PSA-NCAM and synaptic proteins in the dorsolateral prefrontal cortex of psychiatric disorder patients. Neurosci. Lett. 2012, 530(1):97-102.
43. Grayson D.R., Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology 2013, 38(1):138-166.
44. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., Impagnatiello F., Pandey G., Pesold C., Sharma R., Uzunov D., Costa E. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 2000, 57(11):1061-1069.
45. Hashimoto T., Volk D.W., Eggan S.M., Mirnics K., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 2003, 23(15):6315-6326.
46. Hashimoto T., Arion D., Unger T., Maldonado-Aviles J.G., Morris H.M., Volk D.W., Mirnics K., Lewis D.A. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2008, 13(2):147-161.
47. Hashimoto T., Bazmi H.H., Mirnics K., Wu Q., Sampson A.R., Lewis D.A. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am. J. Psychiatry 2008, 165(4):479-489.
48. Heckers S., Stone D., Walsh J., Shick J., Koul P., Benes F.M. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch. Gen. Psychiatry 2002, 59(6):521-529.
49. Hendry S.H., Jones E.G. Reduction in number of immunostained GABAergic neurones in deprived-eye dominance columns of monkey area 17. Nature 1986, 320(6064):750-753.
50. Hendry S.H., Jones E.G. Activity-dependent regulation of GABA expression in the visual cortex of adult monkeys. Neuron 1988, 1(8):701-712.
51. Hoftman G.D., Lewis D.A. Postnatal developmental trajectories of neural circuits in the primate prefrontal cortex: identifying sensitive periods for vulnerability to schizophrenia. Schizophr. Bull. 2011, 37(3):493-503.
52. Huang H.S., Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS One 2007, 2(8):e809.
53. Huang H.S., Matevossian A., Jiang Y., Akbarian S. Chromatin immunoprecipitation in postmortem brain. J. Neurosci. Methods 2006, 156(1-2):284-292.
54. Huang H.S., Matevossian A., Whittle C., Kim S.Y., Schumacher A., Baker S.P., Akbarian S. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J. Neurosci. 2007, 27(42):11254-11262.
55. Hyde T.M., Lipska B.K., Ali T., Mathew S.V., Law A.J., Metitiri O.E., Straub R.E., Ye T., Colantuoni C., Herman M.M., Bigelow L.B., Weinberger D.R., Kleinman J.E. Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia. J. Neurosci. 2011, 31(30):11088-11095.
56. Impagnatiello F., Guidotti A.R., Pesold C., Dwivedi Y., Caruncho H., Pisu M.G., Uzunov D.P., Smalheiser N.R., Davis J.M., Pandey G.N., Pappas G.D., Tueting P., Sharma R.P., Costa E. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(26):15718-15723.
57. Jones E.G., Huntley G.W., Benson D.L. Alpha calcium/calmodulin-dependent protein kinase II selectively expressed in a subpopulation of excitatory neurons in monkey sensory-motor cortex: comparison with GAD-67 expression. J. Neurosci. 1994, 14(2):611-629.
58. Joshi D., Fung S.J., Rothwell A., Weickert C.S. Higher gamma-aminobutyric acid neuron density in the white matter of orbital frontal cortex in schizophrenia. Biol. Psychiatry 2012, 72(9):725-733.
59. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27(7):1081-1090.
60. Kim D.H., Stahl S.M. Antipsychotic drug development. Curr. Top. Behav. Neurosci. 2010, 4:123-139.
61. Kirkpatrick B., Conley R.C., Kakoyannis A., Reep R.L., Roberts R.C. Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: an unbiased cell-counting study. Synapse 1999, 34(2):95-102.
62. Kolb B., Mychasiuk R., Muhammad A., Li Y., Frost D.O., Gibb R. Experience and the developing prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(Suppl. 2):17186-17193.
63. Konermann S., Brigham M.D., Trevino A.E., Hsu P.D., Heidenreich M., Cong L., Platt R.J., Scott D.A., Church G.M., Zhang F. Optical control of mammalian endogenous transcription and epigenetic states. Nature 2013, 500(7463):472-476.
64. Kurita M., Holloway T., Garcia-Bea A., Kozlenkov A., Friedman A.K., Moreno J.L., Heshmati M., Golden S.A., Kennedy P.J., Takahashi N., Dietz D.M., Mocci G., Gabilondo A.M., Hanks J., Umali A., Callado L.F., Gallitano A.L., Neve R.L., Shen L., Buxbaum J.D., Han M.H., Nestler E.J., Meana J.J., Russo S.J., Gonzalez-Maeso J. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 2012, 15(9):1245-1254.
65. Lau C.G., Murthy V.N. Activity-dependent regulation of inhibition via GAD67. J. Neurosci. 2012, 32(25):8521-8531.
66. Lazarus M.S., Krishnan K., Huang Z.J. GAD67 deficiency in parvalbumin interneurons produces deficits in inhibitory transmission and network disinhibition in mouse prefrontal cortex. Cereb. Cortex 2013, (Epub ahead of print). 10.1093/cercor/bht322.
67. Lee J.S., Chun J.W., Yoon S.Y., Park H.J., Kim J.J. Involvement of the mirror neuron system in blunted affect in schizophrenia. Schizophr. Res. 2014, 152(1):268-274.
68. Lett T.A., Voineskos A.N., Kennedy J.L., Levine B., Daskalakis Z.J. Treating working memory deficits in schizophrenia: a review of the neurobiology. Biol. Psychiatry 2014, 75(5):361-370.
69. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience 2005, 6(4):312-324.
70. Lewis D.A., Cho R.Y., Carter C.S., Eklund K., Forster S., Kelly M.A., Montrose D. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 2008, 165(12):1585-1593.
71. Li M., Suzuki K., Kim N.Y., Liu G.H., Izpisua Belmonte J.C. A cut above the rest: targeted genome editing technologies in human pluripotent stem cells. J. Biol. Chem. 2014, 289(8):4594-4599.
72. Lichtshtein D., Dobkin J., Ebstein R.P., Biederman J., Rimon R., Belmaker R.H. Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment. Br. J. Psychiatry 1978, 132:145-148.
73. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
74. Lipska B.K., Lerman D.N., Khaing Z.Z., Weickert C.S., Weinberger D.R. Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. Eur. J. Neurosci. 2003, 18(2):391-402.
75. Mackowiak M., Bator E., Latusz J., Mordalska P., Wedzony K. Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex. Eur. Neuropsychopharmacol. 2014, 24(2):271-289.
76. Matevossian A., Akbarian S. A chromatin assay for human brain tissue. J. Vis. Exp. 2008, (13).
77. Mellios N., Huang H.S., Baker S.P., Galdzicka M., Ginns E., Akbarian S. Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol. Psychiatry 2009, 65(12):1006-1014.
78. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28(1):53-67.
79. Mitchell A.C., Bharadwaj R., Whittle C., Krueger W., Mirnics K., Hurd Y., Rasmussen T., Akbarian S. The genome in three dimensions: a new frontier in human brain research. Biol. Psychiatry 2014, 75(12):961-969.
80. Ota M., Ishikawa M., Sato N., Okazaki M., Maikusa N., Hori H., Hattori K., Teraishi T., Ito K., Kunugi H. Pseudo-continuous arterial spin labeling MRI study of schizophrenic patients. Schizophr. Res. 2014, 154(1-3):113-118.
81. Perry T.L., Kish S.J., Buchanan J., Hansen S. Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet 1979, 1(8110):237-239.
82. Pierri J.N., Chaudry A.S., Woo T.U., Lewis D.A. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am. J. Psychiatry 1999, 156(11):1709-1719.
83. Radhu N., Ravindran L.N., Levinson A.J., Daskalakis Z.J. Inhibition of the cortex using transcranial magnetic stimulation in psychiatric populations: current and future directions. J. Psychiatry Neurosci. 2012, 37(6):369-378.
84. Ribeiro de Almeida C., Stadhouders R., de Bruijn M.J., Bergen I.M., Thongjuea S., Lenhard B., van Ijcken W., Grosveld F., Galjart N., Soler E., Hendriks R.W. The DNA-binding protein CTCF limits proximal Vkappa recombination and restricts kappa enhancer interactions to the immunoglobulin kappa light chain locus. Immunity 2011, 35(4):501-513.
85. Richetto J., Calabrese F., Riva M.A., Meyer U. Prenatal immune activation induces maturation-dependent alterations in the prefrontal GABAergic transcriptome. Schizophr. Bull. 2014, 40(2):351-361.
86. Rioux L., Nissanov J., Lauber K., Bilker W.B., Arnold S.E. Distribution of microtubule-associated protein MAP2-immunoreactive interstitial neurons in the parahippocampal white matter in subjects with schizophrenia. Am. J. Psychiatry 2003, 160(1):149-155.
87. Roberts E., Frankel S. gamma-Aminobutyric acid in brain: its formation from glutamic acid. J. Biol. Chem. 1950, 187(1):55-63.
88. Roberts E., Frankel S. Glutamic acid decarboxylase in brain. J. Biol. Chem. 1951, 188(2):789-795.
89. Rodriguez-Murillo L., Gogos J.A., Karayiorgou M. The genetic architecture of schizophrenia: new mutations and emerging paradigms. Annu. Rev. Med. 2012, 63:63-80.
90. Rowland L.M., Edden R.A., Kontson K., Zhu H., Barker P.B., Hong L.E. GABA predicts inhibition of frequency-specific oscillations in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 2013, 25(1):83-87.
91. Rudolph U., Mohler H. GABAA receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev. Pharmacol. Toxicol. 2014, 54:483-507.
92. Schmidt M.J., Horvath S., Ebert P., Norris J.L., Seeley E.H., Brown J., Gellert L., Everheart M., Garbett K.A., Grice T.W., Caprioli R.M., Mirnics K. Modulation of behavioral networks by selective interneuronal inactivation. Mol. Psychiatry 2014, 19(5):580-587.
93. Sheng G., Demers M., Subburaju S., Benes F.M. Differences in the circuitry-based association of copy numbers and gene expression between the hippocampi of patients with schizophrenia and the hippocampi of patients with bipolar disorder. Arch. Gen. Psychiatry 2012, 69(6):550-561.
94. Shetty A.K., Turner D.A. Glutamic acid decarboxylase-67-positive hippocampal interneurons undergo a permanent reduction in number following kainic acid-induced degeneration of ca3 pyramidal neurons. Exp. Neurol. 2001, 169(2):276-297.
95. Singh D., Chan J.M., Zoppoli P., Niola F., Sullivan R., Castano A., Liu E.M., Reichel J., Porrati P., Pellegatta S., Qiu K., Gao Z., Ceccarelli M., Riccardi R., Brat D.J., Guha A., Aldape K., Golfinos J.G., Zagzag D., Mikkelsen T., Finocchiaro G., Lasorella A., Rabadan R., Iavarone A. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337(6099):1231-1235.
96. Smythies J.R., Bradley R.J., Linton P.H. Meeting report: biochemical aspects of schizophrenia. Alabama, April 1975. Psychoneuroendocrinology 1975, 1(2):199-201.
97. Snitz B.E., MacDonald A., Cohen J.D., Cho R.Y., Becker T., Carter C.S. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am. J. Psychiatry 2005, 162(12):2322-2329.
98. Spokes E.G., Garrett N.J., Rossor M.N., Iversen L.L. Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. J. Neurol. Sci. 1980, 48(3):303-313.
99. Stadler F., Kolb G., Rubusch L., Baker S.P., Jones E.G., Akbarian S. Histone methylation at gene promoters is associated with developmental regulation and region-specific expression of ionotropic and metabotropic glutamate receptors in human brain. J. Neurochem. 2005, 94(2):324-336.
100. Stan A.D., Lewis D.A. Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies. Curr. Pharm. Biotechnol. 2012, 13(8):1557-1562.
101. Stevens J., Wilson K., Foote W. GABA blockade, dopamine and schizophrenia: experimental studies in the cat. Psychopharmacologia 1974, 39(2):105-119.
102. Straub R.E., Lipska B.K., Egan M.F., Goldberg T.E., Callicott J.H., Mayhew M.B., Vakkalanka R.K., Kolachana B.S., Kleinman J.E., Weinberger D.R. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol. Psychiatry 2007, 12(9):854-869.
103. Streit M., Ioannides A., Sinnemann T., Wolwer W., Dammers J., Zilles K., Gaebel W. Disturbed facial affect recognition in patients with schizophrenia associated with hypoactivity in distributed brain regions: a magnetoencephalographic study. Am. J. Psychiatry 2001, 158(9):1429-1436.
104. Swartz M.S., Perkins D.O., Stroup T.S., Davis S.M., Capuano G., Rosenheck R.A., Reimherr F., McGee M.F., Keefe R.S., McEvoy J.P., Hsiao J.K., Lieberman J.A. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 2007, 164(3):428-436.
105. Taly A. Novel approaches to drug design for the treatment of schizophrenia. Expert Opin. Drug Discovery 2013, 8(10):1285-1296.
106. Tamminga C.A., Crayton J.W., Chase T.N. Muscimol: GABA agonist therapy in schizophrenia. Am. J. Psychiatry 1978, 135(6):746-747.
107. Tang B., Dean B., Thomas E.A. Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Transl. Psychiatry 2011, 1:e64.
108. Tao R., Li C., Newburn E.N., Ye T., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E., Hyde T.M. Transcript-specific associations of SLC12A5 (KCC2) in human prefrontal cortex with development, schizophrenia, and affective disorders. J. Neurosci. 2012, 32(15):5216-5222.
109. Thompson Ray M., Weickert C.S., Wyatt E., Webster M.J. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry. Neurosci. 2011, 36(3):195-203.
110. Thoresen C., Endestad T., Sigvartsen N.P., Server A., Bolstad I., Johansson M., Andreassen O.A., Jensen J. Frontotemporal hypoactivity during a reality monitoring paradigm is associated with delusions in patients with schizophrenia spectrum disorders. Cogn. Neuropsychiatry 2014, 19(2):97-115.
111. Todtenkopf M.S., Benes F.M. Distribution of glutamate decarboxylase65 immunoreactive puncta on pyramidal and nonpyramidal neurons in hippocampus of schizophrenic brain. Synapse 1998, 29(4):323-332.
112. Torrey E.F., Barci B.M., Webster M.J., Bartko J.J., Meador-Woodruff J.H., Knable M.B. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry 2005, 57(3):252-260.
113. van Berkum N.L., Dekker J. Determining spatial chromatin organization of large genomic regions using 5C technology. Methods Mol. Biol. 2009, 567:189-213.
114. van Kammen D.P., Sternberg D.E., Hare T.A., Waters R.N., Bunney W.E. CSF levels of gamma-aminobutyric acid in schizophrenia. Low values in recently ill patients. Arch. Gen. Psychiatry 1982, 39(1):91-97.
115. Veldic M., Guidotti A., Maloku E., Davis J.M., Costa E. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(6):2152-2157.
116. Veldic M., Kadriu B., Maloku E., Agis-Balboa R.C., Guidotti A., Davis J.M., Costa E. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr. Res. 2007, 91(1-3):51-61.
117. Volk D.W., Austin M.C., Pierri J.N., Sampson A.R., Lewis D.A. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 2000, 57(3):237-245.
118. Volk D.W., Pierri J.N., Fritschy J.M., Auh S., Sampson A.R., Lewis D.A. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb. Cortex 2002, 12(10):1063-1070.
119. Volk D.W., Matsubara T., Li S., Sengupta E.J., Georgiev D., Minabe Y., Sampson A., Hashimoto T., Lewis D.A. Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia. Am. J. Psychiatry 2012, 169(10):1082-1091.
120. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44(7):660-669.
121. Wolwer W., Stroth S., Brinkmeyer J., Gaebel W. Electrophysiological correlates of planning and monitoring in first episode schizophrenia. Psychiatry Res. 2012, 203(1):83-88.
122. Woo T.U., Whitehead R.E., Melchitzky D.S., Lewis D.A. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(9):5341-5346.
123. Yang Y., Fung S.J., Rothwell A., Tianmei S., Weickert C.S. Increased interstitial white matter neuron density in the dorsolateral prefrontal cortex of people with schizophrenia. Biol. Psychiatry 2011, 69(1):63-70.
124. Yoon J.H., Maddock R.J., Rokem A., Silver M.A., Minzenberg M.J., Ragland J.D., Carter C.S. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J. Neurosci. 2010, 30(10):3777-3781.
125. Yoon J.H., Minzenberg M.J., Raouf S., D'Esposito M., Carter C.S. Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol. Psychiatry 2013, 74(2):122-129.
126. Zhang T.Y., Hellstrom I.C., Bagot R.C., Wen X., Diorio J., Meaney M.J. Maternal care and DNA methylation of a glutamic acid decarboxylase 1 promoter in rat hippocampus. J. Neurosci. 2010, 30(39):13130-13137.
127. Zhu J., Adli M., Zou J.Y., Verstappen G., Coyne M., Zhang X., Durham T., Miri M., Deshpande V., De Jager P.L., Bennett D.A., Houmard J.A., Muoio D.M., Onder T.T., Camahort R., Cowan C.A., Meissner A., Epstein C.B., Shoresh N., Bernstein B.E. Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell 2013, 152(3):642-654.